Description:

ProVascTec is a pre-clinical stage cell therapy company with a proprietary technology to increase the efficacy of cell therapies by increasing the pay-load delivery and prolonging the viability of cells. Co-founded by a leading vascular biologist and an experienced pharma manager, ProVascTec’s lead product aims to improve the life of patients suffering from blocked arteries in the lower extremeties, a medical condition referred to a critical limb ischemia. With 5.0m patients in the US, Europe, and Japan, ProVascTec targets a market of € 16bn.